Prevention of Reintubation by Using Noninvasive Positive Pressure Ventilation
Primary Purpose
Extubation Failure, Acute Respiratory Failure Post Extubation
Status
Unknown status
Phase
Phase 3
Locations
Brazil
Study Type
Interventional
Intervention
Positive Pressure Noninvasive ventilation
Inhalatory O2
Sponsored by
About this trial
This is an interventional treatment trial for Extubation Failure focused on measuring noninvasive ventilation, extubation, Respiratory failure, reintubation
Eligibility Criteria
Inclusion Criteria:
Patients aged between 28 days and 15 years and who were intubated and remained under invasive mechanical ventilation for 48 hours, passed in the extubation test for, and who presented at least one of the following risk factors for respiratory distress post extubation:
- Invasive ventilation for at least 15 days
- Use of inotropics for more than 48 hours
- Endovenous continuous administration of sedative/analgesic drugs
- 1-3 months old
- Mean Airway Pressure(Paw)> 8,5; Inspired fraction of O2(FiO2)> 0,4; Oxygenation index(IO)> 4,5 immediately before extubation
- Cardiac or pulmonary chronic diseases
- Cardiac output
- Hipercapny: Arterial pressure of CO2 (PaCO2)> 45 mmHg
Exclusion Criteria:
- Tracheostomized
- Accidental extubation
- Respiratory failure just after extubation, needing immediate reintubation
- Neuromuscular diseases
- Death
- PPNIV exclusion: coma or disability to protect airway, not tolerated, hemodynamic instability, shock, cardiac disritmy, facial or intracranial traumatic injury or surgery that preclude use of mask, abdominal distension, nausea or vomiting, gastric or esophagic recent surgery, gastrointestinal hemorrhagy in activity, not drained pneumothorax.
- Reintubated patients during its stay in PICU, that have already participated in this study
Sites / Locations
- Botucatu Medical School-UNESPRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
PPNIV
O2I
Arm Description
Patient randomized to this group will be ventilated with Positive Pressure Noninvasive Ventilation post extubation
Patient randomized to this group will be submitted to traditional oxygen therapy post extubation
Outcomes
Primary Outcome Measures
Prevention of reintubation
Secondary Outcome Measures
decrease of PICU and hospital mortality
decrease of hospital and PICU length of stay
Full Information
NCT ID
NCT00977002
First Posted
September 14, 2009
Last Updated
February 1, 2011
Sponsor
UPECLIN HC FM Botucatu Unesp
1. Study Identification
Unique Protocol Identification Number
NCT00977002
Brief Title
Prevention of Reintubation by Using Noninvasive Positive Pressure Ventilation
Official Title
Prevention of Reintubation by Using Noninvasive Positive Pressure Ventilation: Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
February 2011
Overall Recruitment Status
Unknown status
Study Start Date
March 2008 (undefined)
Primary Completion Date
December 2009 (Anticipated)
Study Completion Date
December 2010 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
UPECLIN HC FM Botucatu Unesp
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Child extubation failure range from 4.1% to 19%. Studies in adults and children showed that extubation failure increases mortality mainly in those who need reintubation as this is a invasive procedure associated with many complications. Therefore, patients are reintubated when they worsen, which can contribute to organ dysfunction and increased mortality.
Positive Pressure Noninvasive ventilation (PPNIV) has been proposed as a way to treat acute respiratory distress, avoiding complications of intubation and invasive ventilation. Most of the studies in adults are not conclusive on the benefits of PPNIV as a way to treat post-extubation acute respiratory distress. However, studies that evaluated the early use of PPNIV in post-extubation period as a way to prevent respiratory failure tend to show some advantages as decrease of reintubation, decrease number of respiratory distress, decrease of hospital infection frequency and lower mortality rate in the intensive care unit (ICU) for those who use PPNIV.
In a prospective study on the use of PPNIV in 114 children, Essouri at al avoided invasive ventilation in 77%, being the group in patients with post-extubation respiratory distress.
As far as the investigators know there is not any randomized, controlled study in children examining the PPNIV as a way to prevent post-extubation respiratory distress. The investigators' hypothesis is that PPNIV decreases the extubation failure rate and, as a consequence, the Pediatric Intensive Care Unit (PICU) and hospital length of stay, and mortality rate.
The objective is to compare PPNIV and inhalatory O2 (catheter or facial mask) in children after extubation, evaluating the need of reintubation, hospital and PICU mortality rate and length of stay in PICU and hospital.
Detailed Description
Prospective, randomized and controlled study at the PICU - University Hospital, Botucatu Medical School-UNESP. Patients elegibled are exposed to extubation test. If passed they are randomized in two groups: 1) post-extubation PPNIV (PPNIV, n=50), and 2) Inhalatory oxygen therapy by nasal catheter or facial mask (O2I, n=50). Patients are observed for 48 hours, being considered extubation failure if they need reintubation. Arterial blood gas is obtained at the day or programed extubation and one hour after extubation.
Nasal prongs and facial or nasal masks are used in accordance with child age. All patients from this group are kept in PPNIV for a 12 hours at least. Feeding, if released, is done by gastric probe.
In O2IG, patients use facial mask or nasal catheter after extubation. Both groups are submitted to physiotherapy and nurse care as the PICU routine Follow up: Variables: age, gender, disease and comorbidities, intubation cause , time intubated and invasive ventilation use, PRISM score at the moment of admission, risk factors to respiratory distress post extubation, Comfort scale just before extubation, use of sedatives (time and mean dose)during invasive ventilation. At randomization and one hour later: vital signs, arterial blood gas. Patients are followed for 48 hour to evaluate reintubation and then for other complications, death and length of stay in PICU and hospital.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Extubation Failure, Acute Respiratory Failure Post Extubation
Keywords
noninvasive ventilation, extubation, Respiratory failure, reintubation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PPNIV
Arm Type
Experimental
Arm Description
Patient randomized to this group will be ventilated with Positive Pressure Noninvasive Ventilation post extubation
Arm Title
O2I
Arm Type
Active Comparator
Arm Description
Patient randomized to this group will be submitted to traditional oxygen therapy post extubation
Intervention Type
Other
Intervention Name(s)
Positive Pressure Noninvasive ventilation
Other Intervention Name(s)
Noninvasive ventilation
Intervention Description
Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.
Intervention Type
Other
Intervention Name(s)
Inhalatory O2
Other Intervention Name(s)
Oxygen therapy
Intervention Description
Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
Primary Outcome Measure Information:
Title
Prevention of reintubation
Time Frame
48 hours
Secondary Outcome Measure Information:
Title
decrease of PICU and hospital mortality
Time Frame
28 days
Title
decrease of hospital and PICU length of stay
Time Frame
28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
28 Days
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients aged between 28 days and 15 years and who were intubated and remained under invasive mechanical ventilation for 48 hours, passed in the extubation test for, and who presented at least one of the following risk factors for respiratory distress post extubation:
Invasive ventilation for at least 15 days
Use of inotropics for more than 48 hours
Endovenous continuous administration of sedative/analgesic drugs
1-3 months old
Mean Airway Pressure(Paw)> 8,5; Inspired fraction of O2(FiO2)> 0,4; Oxygenation index(IO)> 4,5 immediately before extubation
Cardiac or pulmonary chronic diseases
Cardiac output
Hipercapny: Arterial pressure of CO2 (PaCO2)> 45 mmHg
Exclusion Criteria:
Tracheostomized
Accidental extubation
Respiratory failure just after extubation, needing immediate reintubation
Neuromuscular diseases
Death
PPNIV exclusion: coma or disability to protect airway, not tolerated, hemodynamic instability, shock, cardiac disritmy, facial or intracranial traumatic injury or surgery that preclude use of mask, abdominal distension, nausea or vomiting, gastric or esophagic recent surgery, gastrointestinal hemorrhagy in activity, not drained pneumothorax.
Reintubated patients during its stay in PICU, that have already participated in this study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rafaelle F Batistella, MD
Phone
+55-1438116300
Email
rafaellefb@yahoo.com.br
First Name & Middle Initial & Last Name or Official Title & Degree
José R Fioretto, MD, PhD
Phone
+55-1438116274
Email
jrf@fmb.unesp.br
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rafaelle F Batistella
Organizational Affiliation
FMB - UNESP
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
José R Fioretto
Organizational Affiliation
FMB-UNESP
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Mário F Carpi
Organizational Affiliation
FMB-UNESP
Official's Role
Study Chair
Facility Information:
Facility Name
Botucatu Medical School-UNESP
City
Botucatu
State/Province
Sao Paulo
ZIP/Postal Code
18.618-970
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rafaelle F Batistella, MD
Phone
+55-1438116300
Email
rafaellefb@yahoo.com.br
First Name & Middle Initial & Last Name & Degree
José R Fioretto, MD, PhD
Phone
+55-1438116274
Email
jrf@fmb.unesp.br
First Name & Middle Initial & Last Name & Degree
Rafaelle F Batistella, MD
First Name & Middle Initial & Last Name & Degree
José R Fioretto, PhD
First Name & Middle Initial & Last Name & Degree
Mário F Carpi, PhD
12. IPD Sharing Statement
Learn more about this trial
Prevention of Reintubation by Using Noninvasive Positive Pressure Ventilation
We'll reach out to this number within 24 hrs